Aclaris Therapeutics (ACRS) Insider Trading & Ownership $1.86 +0.02 (+0.82%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aclaris Therapeutics (NASDAQ:ACRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.60%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$1.50MNumber OfInsiders Selling(Last 12 Months)0 Get ACRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Aclaris Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACRS Insider Buying and Selling by Quarter Aclaris Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/19/2024Anand MehraDirectorBuy666,666$2.25$1,499,998.50 (Data available from 1/1/2013 forward) ACRS Insider Trading Activity - Frequently Asked Questions Who is on Aclaris Therapeutics' Insider Roster? The list of insiders at Aclaris Therapeutics includes Anand Mehra, Andrew N Schiff, Braden Michael Leonard, Douglas J Manion, James Loerop, Joseph Monahan, Kevin Balthaser, and Neal Walker. Learn more on insiders at ACRS. What percentage of Aclaris Therapeutics stock is owned by insiders? 5.60% of Aclaris Therapeutics stock is owned by insiders. Learn more on ACRS's insider holdings. Which Aclaris Therapeutics insiders have been buying company stock? The following insiders have purchased ACRS shares in the last 24 months: Anand Mehra ($1,499,998.50), and Braden Michael Leonard ($2,976,645.92). How much insider buying is happening at Aclaris Therapeutics? Insiders have purchased a total of 3,275,789 ACRS shares in the last 24 months for a total of $4,476,644.42 bought. Which Aclaris Therapeutics insiders have been selling company stock? The following insider sold ACRS shares in the last 24 months: Joseph Monahan ($30,480.00). How much insider selling is happening at Aclaris Therapeutics? Insiders have sold a total of 6,000 Aclaris Therapeutics shares in the last 24 months for a total of $30,480.00 sold. Aclaris Therapeutics Key ExecutivesDr. Neal S. Walker D.O. (Age 54)M.D., Co-Founder, President, Chairman & Interim CEO Compensation: $73.5kMr. Kevin Balthaser (Age 36)Chief Financial Officer Compensation: $581.52kDr. Joseph Monahan Ph.D. (Age 67)Chief Scientific Officer Compensation: $492.43kMr. James Loerop (Age 59)Chief Business Officer Compensation: $570kMr. Matthew Rothman J.D.General Counsel & Corporate SecretaryDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryMr. Steve TuckerSenior Vice President of Project LeadershipMr. Ajay Aggarwal M.B.A.M.D., Senior Vice President of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Mind Medicine (MindMed) Insider Buying Nurix Therapeutics Insider Buying Tango Therapeutics Insider Buying Ginkgo Bioworks Insider Buying Day One Biopharmaceuticals Insider Buying ProKidney Insider Buying Theravance Biopharma Insider Buying KalVista Pharmaceuticals Insider Buying Kura Oncology Insider Buying Bicara Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:ACRS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access